A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
This clinical trial is designed as a randomized, placebo-controlled, single-blind, parallel
 design, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in
 patients with benign prostatic hyperplasia. Eligible subjects are randomized into a group out
 of the three study groups and a placebo group after four weeks of placebo run-in period.
 Placebo run-in period is concurrently proceeded as a wash-out period for previous treatment
 of benign prostatic hyperplasia, and a placebo is administered intradermally twice with
 two-week interval during this period. After that, the randomized subjects receive a study
 drug and a placebo intradermally seven times with two-week interval by visiting at Week 0, 2,
 4, 6, 8, 10, and 12. After the treatment period, the subjects additionally visit at Week 13
 and 16, and the efficacy is evaluated at Week 4, 8, 12, 13, and 16, and the safety is
 evaluated over the 16-week period.
Patients will be randomized equally between the four arms.

 1. Control group (placebo, two-week interval): 38 subjects

 2. Study group 1 (GV1001 0.4 mg, intradermal administration, two-week interval): 38
 subjects

 3. Study group 2 (GV1001 0.56 mg, intradermal administration, two-week interval): 38
 subjects

 4. Study group 3 (GV1001 0.56 mg, intradermal administration, four-week interval): 38
 subjects
[Inclusion Criteria]

 All of the following criteria should be satisfied to be enrolled in this clinical trial.

 1. A male at 50 years of age and older

 2. A patient who satisfies the following clinical signs and symptoms of benign prostatic
 hyperplasia

 ① A patient with a volume of prostate gland (TRUS) > 30 cc

 ② A patient with moderate to severe lower urinary tract symptoms with IPSS ≥ 13

 ③ A patient with 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume
 was at least 125 mL

 3. A patient with PSA level < 10 ng/mL (however, if 4 ng/mL < PSA < 10 ng/mL, a person
 with a biopsy result, confirming that he does not have prostate cancer)

 4. A patient with residual urine volume ≤ 200 mL

 5. A patient with intention of not using drugs which may affect benign prostatic
 hyperplasia (5-alpha reductase inhibitors, drugs similar to LHRH, alpha blockers,
 alpha-beta blockers, anticholinergics, antidiuretic hormones, diuretics, PDE-5
 inhibitors, beta-3 adrenoceptor antagonists, etc.), drugs affecting immune system
 (steroids, immunosuppressants), or health functional foods which may affect a prostate
 gland (saw palmetto, etc.) during the clinical trial period

 6. A patient has to consent not to participate in other clinical trials as a subject
 during this clinical trial period.

 7. Before enrollment to the study, a patient has to consent to avoid pregnancy by using
 condoms for 90 days after the end of study participation period and treatment.
 (However, this is not applied if the patient had vasectomy.) Also, a partner of the
 patient has to consent to avoid pregnancy by using contraceptive devices or oral
 contraceptives during the patient's participation in clinical trial and for 90 days
 after the end of treatment, except if the partner reaches menopause or is surgically
 sterilized. (Consent should be obtained before visit 4, when necessary.)

 [Exclusion Criteria]

 If any one of the following is applied, a patient cannot be enrolled in this clinical
 trial.

 1. A patient who has hypersensitivity reactions to ingredients of this drug.

 2. A patient who received 5-alpha reductase inhibitors other than a drug used in this
 clinical trial before randomization (within six months)

 3. A patient who received drugs similar to LHRH other than a drug used in this clinical
 trial

 4. A patient who has received an unapproved study drug in the past or the study drug for
 this clinical trial (One exception: a patient can be enrolled when the drug is
 considered by an investigator not to affect prostate and urinary function, and the
 patient is not participating in other ongoing clinical trial.)

 5. If diagnosed with prostate cancer in the past or at present

 6. A patient who was considered by an investigator to have an influence to an evaluation
 on urine flow symptoms due to other previous or current diseases besides benign
 prostatic hyperplasia (e.g., neurogenic bladder, bladder neck contracture, urethral
 stricture, bladder cancer, malignant tumor in lower urinary tract, etc.)

 7. A patient who had surgeries or radiation therapies for prostate gland, bladder or
 pelvis, or who had invasive treatments for benign prostatic hyperplasia

 8. A patient who has severe medical condition which may be cause problem to conduct the
 clinical trial (e.g., chronic heart failure (CHF), difficult-to-control diabetes
 (HbA1c > 7%), mental disorder, drug, or alcohol abuse, etc.)

 9. A patient with moderate to severe liver hypofunction and severe kidney hypofunction
 (less than 30 mL/min of creatinine clearance)

 10. A patient who receives drugs affecting immune system (e.g., immunosuppressives,
 steroids for systemic action, etc.)

 11. Any other patients who are considered to be ineligible for this study by an
 investigator

 [Inclusion Criteria for Randomization]

 1. A patient who satisfies the following clinical signs and symptoms of benign prostatic
 hyperplasia

 ① A patient with a volume of prostate gland (TRUS) > 30 cc *

 ② A patient with moderate to severe lower urinary tract symptoms with IPSS ≥ 13

 ③ A patient with 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume
 was at least 125 mL

 2. A patient with residual urine volume ≤ 200 mL

 3. A partner of the patient has to consent to avoid pregnancy by using contraceptive
 devices or oral contraceptives during the patient's participation in clinical trial
 and for 90 days after the end of treatment, except if the partner reaches menopause or
 is surgically sterilized.

 (* In case that additional TRUS examination has been performed after screening, a decision
 should be made based on the latest result.)